Int J Cancer: Comparison of the efficacy of docetaxel + carboplatin vs epirubicin + cyclophosphamide in the treatment of early triple-negative breast cancer with docetaxel neoadjuvant chemotherapy: a multicenter randomized controlled study (NeoCART)

Studies have shown that patients with triple- negative breast cancer ( TNBC ) have a poor prognosis due to the lack of targeted therapy
.

Despite the progress made in treatment, cytotoxic chemotherapy is still the basis of TNBC treatment

Studies have shown that patients with triple- negative breast cancer ( TNBC ) have a poor prognosis due to the lack of targeted therapy

The NeoCART study is a multi-center, randomized controlled, open-label, phase 2 clinical study that evaluates docetaxel + carboplatin (DCb) vs epirubicin + cyclophosphamide in patients with early TNBC ( phase II-III ) Comparison of the efficacy of docetaxel (EC-D ) as a neoadjuvant chemotherapy
.

The primary study endpoint is the pathological complete remission rate ( pCR (ypT0/is ypN0))

The NeoCART study is a multi-center, randomized controlled, open-label, phase 2 clinical study that evaluates docetaxel + carboplatin (DCb) vs epirubicin + cyclophosphamide in patients with early TNBC ( phase II-III ) Comparison of the efficacy of docetaxel (EC-D ) as a neoadjuvant chemotherapy

In 2016 years .
9 dated .
1 to 2019 years 12 is dated 31 is the date from .

In the primary endpoint analysis , 27 patients in the DCb group achieved pCR (61.
4%, 95% CI 47.
0-75.
8), and 17 patients in the EC-D group achieved pCR (38.

pCR comparison

pCR vs.
pCR vs.

Among stage II patients, the pCR rates of DCb group and EC-D group were 73.
3% (22/30) and 48.
4% (15/31) (95% CI 1.
2 48.
6; p = 0.
046), respectively.
Two groups of stage III patients The pCR rates were 35.
7% (5/14) and 15.
4% (2/13) (95% CI -11.
5-52.
2; p = 0.
384)
.

Among stage II patients, the pCR rates of DCb group and EC-D group were 73.
3% (22/30) and 48.
4% (15/31) (95% CI 1.
2 48.
6; p = 0.
046), respectively.
Two groups of stage III patients The pCR rates were 35.
7% (5/14) and 15.
4% (2/13) (95% CI -11.
5-52.
2; p = 0.
384)
.

The median follow-up time was 37 months, and the distribution of 3-year EFS rates in the DCb group and EC-D group was 90.
8% (95%CI 82.
6-99.
8%) and 88.
3% (79.
2-98.
5%) (HR=0.
76, 95%) CI 0.
2–2.
84, P = 0.
683); the 3-year OS rates of the two groups were 92.
8% (85.
3-100%) and 93.
1% (85.
8 -100%) (HR=0.
96, 95% CI 0.
19 4.
76, P=0.
959) )
.

Compared with patients with residual disease, EFS and OS were significantly higher in obtaining pCR

The median follow-up time was 37 months, and the distribution of 3-year EFS rates in the DCb group and EC-D group was 90.

           EFS and OS rate

           EFS and OS rate EFS and OS rate

The DCb regimen increased the overall incidence of thrombocytopenia (20.
5%)
.

In the DCb group, grade 3/4 adverse events included anemia (4.

The DCb regimen increased the overall incidence of thrombocytopenia (20.

             Adverse reactions

             Adverse reactions adverse reactions

In summary, the NeoCART study shows that docetaxel + carboplatin (DCb) is more effective than epirubicin + cyclophosphamide as a neoadjuvant chemotherapy for early triple-negative breast cancer (TNBC).
) Patients get a higher pCR rate
.

In summary, the NeoCART study shows that docetaxel + carboplatin (DCb) is more effective than epirubicin + cyclophosphamide as a neoadjuvant chemotherapy for early triple-negative breast cancer (TNBC).
) Patients get a higher pCR rate
.

In summary, the NeoCART study shows that docetaxel + carboplatin (DCb) is more effective than epirubicin + cyclophosphamide as a neoadjuvant chemotherapy for early triple-negative breast cancer (TNBC).
) Patients get a higher pCR rate
.
NeoCART research has shown that docetaxel + carboplatin (DCb) is better than epirubicin + cyclophosphamide and continued docetaxel (EC-D) as a neoadjuvant chemotherapy for early triple-negative breast cancer (TNBC) patients.
Higher pCR rate
.

Original source:

Original source:

Zhang L, Wu ZY, Li J, Lin Y, Liu Z, Cao Y, Zhang G, Gao HF, Yang M, Yang CQ, Zhu T, Cheng MY, Ji F, Li J, Wang K.
Neoadjuvant Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel in Triple-Negative, Early-Stage Breast Cancer (NeoCART): Results from a Multicenter, Randomized Controlled, Open-Label Phase II Trial.
Int J Cancer.
2021 Sep 30.
doi: 10.
1002/ijc.
33830 .
Epub ahead of print.
PMID: 34591977.

Zhang L, Wu ZY, Li J, Lin Y, Liu Z, Cao Y, Zhang G, Gao HF, Yang M, Yang CQ, Zhu T, Cheng MY, Ji F, Li J, Wang K.
Neoadjuvant Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel in Triple-Negative, Early-Stage Breast Cancer (NeoCART): Results from a Multicenter, Randomized Controlled, Open-Label Phase II Trial.
Int J Cancer.
2021 Sep 30.
doi: 10.
1002/ijc.
33830 .
Epub ahead of print.
PMID: 34591977.
Leave a message here